nodes	percent_of_prediction	percent_of_DWPC	metapath
Goserelin—LHCGR—ovarian follicle—hematologic cancer	0.164	0.794	CbGeAlD
Goserelin—LHCGR—gonad—hematologic cancer	0.0151	0.0729	CbGeAlD
Goserelin—Icatibant—ANPEP—hematologic cancer	0.0134	1	CrCbGaD
Goserelin—LHCGR—testis—hematologic cancer	0.0109	0.0525	CbGeAlD
Goserelin—GNRHR—gonad—hematologic cancer	0.00972	0.047	CbGeAlD
Goserelin—GNRHR—testis—hematologic cancer	0.00701	0.0338	CbGeAlD
Goserelin—GNRHR—Signaling Pathways—IL3RA—hematologic cancer	0.000138	0.00083	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PRKCZ—hematologic cancer	0.000138	0.000827	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—RASGRP1—hematologic cancer	0.000136	0.000814	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CG—hematologic cancer	0.000135	0.000808	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—GRB2—hematologic cancer	0.000134	0.000806	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—RGS2—hematologic cancer	0.000133	0.0008	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PARP1—hematologic cancer	0.000133	0.000799	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—hematologic cancer	0.000132	0.000793	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TRH—hematologic cancer	0.000132	0.000791	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CMA1—hematologic cancer	0.000132	0.000791	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TRIO—hematologic cancer	0.000132	0.000791	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FBXW7—hematologic cancer	0.000131	0.000786	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—SPHK1—hematologic cancer	0.000129	0.000774	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AGO2—hematologic cancer	0.000129	0.000774	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HDAC2—hematologic cancer	0.000128	0.00077	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CXCR4—hematologic cancer	0.000128	0.00077	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—LPAR1—hematologic cancer	0.000128	0.000766	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HDAC9—hematologic cancer	0.000128	0.000766	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—H3F3B—hematologic cancer	0.000126	0.000759	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CBL—hematologic cancer	0.000125	0.000751	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—IL3—hematologic cancer	0.000124	0.000743	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CG—hematologic cancer	0.000122	0.000734	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—hematologic cancer	0.000122	0.000734	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—GRB2—hematologic cancer	0.000122	0.000732	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PTPN1—hematologic cancer	0.000122	0.00073	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PTPN11—hematologic cancer	0.00012	0.000721	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—CSF2—hematologic cancer	0.00012	0.00072	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—RASGRP1—hematologic cancer	0.00012	0.000719	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HSP90AA1—hematologic cancer	0.000119	0.000716	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—SYK—hematologic cancer	0.000119	0.000716	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CD—hematologic cancer	0.000118	0.00071	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CNR2—hematologic cancer	0.000118	0.000705	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PDE4B—hematologic cancer	0.000118	0.000705	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—hematologic cancer	0.000117	0.000702	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FGF19—hematologic cancer	0.000117	0.0007	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—CREB1—hematologic cancer	0.000116	0.000699	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—JAK1—hematologic cancer	0.000116	0.000695	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PRKCG—hematologic cancer	0.000116	0.000695	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—RAC2—hematologic cancer	0.000116	0.000694	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—STAT1—hematologic cancer	0.000115	0.000691	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—DKK1—hematologic cancer	0.000115	0.000688	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—CCL2—hematologic cancer	0.000114	0.000684	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—STAT5B—hematologic cancer	0.000114	0.000683	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—IL6R—hematologic cancer	0.000114	0.000681	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3R1—hematologic cancer	0.000112	0.000671	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ADCY7—hematologic cancer	0.000111	0.000663	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—CSF2—hematologic cancer	0.000109	0.000654	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—JAK2—hematologic cancer	0.000109	0.000652	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—MAP2K1—hematologic cancer	0.000108	0.000649	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—IL2RA—hematologic cancer	0.000108	0.000649	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—GRB2—hematologic cancer	0.000108	0.000646	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CD—hematologic cancer	0.000108	0.000645	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—XIAP—hematologic cancer	0.000108	0.000645	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PDGFA—hematologic cancer	0.000107	0.000645	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—KITLG—hematologic cancer	0.000106	0.000635	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—JAK1—hematologic cancer	0.000105	0.000631	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PRKCG—hematologic cancer	0.000105	0.000631	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—SH2B3—hematologic cancer	0.000105	0.000629	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—SMARCA4—hematologic cancer	0.000105	0.000629	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—GZMB—hematologic cancer	0.000104	0.000625	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—STAT5A—hematologic cancer	0.000104	0.000621	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CB—hematologic cancer	0.000103	0.000619	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CDKN2B—hematologic cancer	0.000103	0.000616	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CTNNA1—hematologic cancer	0.000102	0.00061	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3R1—hematologic cancer	0.000102	0.000609	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—EIF4EBP1—hematologic cancer	0.000101	0.000607	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HSPB1—hematologic cancer	0.000101	0.000607	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CCL3—hematologic cancer	0.000101	0.000607	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—SDC1—hematologic cancer	0.0001	0.0006	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PTHLH—hematologic cancer	0.0001	0.0006	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CD86—hematologic cancer	9.93e-05	0.000595	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—JAK2—hematologic cancer	9.87e-05	0.000592	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—IL2RA—hematologic cancer	9.83e-05	0.00059	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HES1—hematologic cancer	9.79e-05	0.000587	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—NCOR1—hematologic cancer	9.73e-05	0.000584	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PTGER4—hematologic cancer	9.73e-05	0.000584	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—LCK—hematologic cancer	9.68e-05	0.000581	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FGF1—hematologic cancer	9.63e-05	0.000577	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CSF2—hematologic cancer	9.63e-05	0.000577	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—H3F3A—hematologic cancer	9.49e-05	0.000569	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FOXO1—hematologic cancer	9.49e-05	0.000569	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—IL2—hematologic cancer	9.48e-05	0.000569	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PDGFRB—hematologic cancer	9.47e-05	0.000568	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CB—hematologic cancer	9.38e-05	0.000562	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PDGFRA—hematologic cancer	9.32e-05	0.000559	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—JAK1—hematologic cancer	9.29e-05	0.000557	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PRKCG—hematologic cancer	9.29e-05	0.000557	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PRKCZ—hematologic cancer	9.23e-05	0.000553	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CG—hematologic cancer	9.02e-05	0.000541	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PARP1—hematologic cancer	8.91e-05	0.000535	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FBXW7—hematologic cancer	8.77e-05	0.000526	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—IL2RA—hematologic cancer	8.68e-05	0.00052	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—IL2—hematologic cancer	8.61e-05	0.000516	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CXCR4—hematologic cancer	8.6e-05	0.000516	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HDAC2—hematologic cancer	8.6e-05	0.000516	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TERT—hematologic cancer	8.58e-05	0.000515	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CBL—hematologic cancer	8.38e-05	0.000503	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PDGFB—hematologic cancer	8.37e-05	0.000502	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IL3—hematologic cancer	8.29e-05	0.000497	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CG—hematologic cancer	8.19e-05	0.000491	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TSC2—hematologic cancer	8.18e-05	0.000491	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PTPN1—hematologic cancer	8.15e-05	0.000489	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PTPN11—hematologic cancer	8.05e-05	0.000483	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—RASGRP1—hematologic cancer	8.02e-05	0.000481	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—SYK—hematologic cancer	7.99e-05	0.000479	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HSP90AA1—hematologic cancer	7.99e-05	0.000479	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CD—hematologic cancer	7.93e-05	0.000476	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FGFR3—hematologic cancer	7.87e-05	0.000472	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—CREB1—hematologic cancer	7.8e-05	0.000468	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MAPK14—hematologic cancer	7.79e-05	0.000468	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—STAT1—hematologic cancer	7.71e-05	0.000462	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ESR1—hematologic cancer	7.65e-05	0.000459	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—CCL2—hematologic cancer	7.63e-05	0.000458	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—IL6R—hematologic cancer	7.61e-05	0.000456	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FN1—hematologic cancer	7.55e-05	0.000453	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3R1—hematologic cancer	7.49e-05	0.000449	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—BAD—hematologic cancer	7.46e-05	0.000448	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—NFKBIA—hematologic cancer	7.46e-05	0.000448	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—NOTCH1—hematologic cancer	7.39e-05	0.000443	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—JAK2—hematologic cancer	7.28e-05	0.000436	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—MAP2K1—hematologic cancer	7.25e-05	0.000435	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CD80—hematologic cancer	7.24e-05	0.000434	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CG—hematologic cancer	7.23e-05	0.000434	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—KIT—hematologic cancer	7.23e-05	0.000434	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—NRAS—hematologic cancer	7.23e-05	0.000434	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—GRB2—hematologic cancer	7.21e-05	0.000433	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CD—hematologic cancer	7.2e-05	0.000432	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PDGFA—hematologic cancer	7.19e-05	0.000431	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PTPN11—hematologic cancer	7.1e-05	0.000426	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—KITLG—hematologic cancer	7.09e-05	0.000425	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—STAT5A—hematologic cancer	6.93e-05	0.000416	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—MAPK3—hematologic cancer	6.92e-05	0.000415	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CB—hematologic cancer	6.91e-05	0.000415	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CREB1—hematologic cancer	6.88e-05	0.000413	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CDKN2B—hematologic cancer	6.87e-05	0.000412	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3R1—hematologic cancer	6.8e-05	0.000408	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—BRAF—hematologic cancer	6.79e-05	0.000408	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CCL2—hematologic cancer	6.73e-05	0.000404	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—IL6R—hematologic cancer	6.71e-05	0.000403	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CREBBP—hematologic cancer	6.7e-05	0.000402	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CD86—hematologic cancer	6.64e-05	0.000399	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—JAK2—hematologic cancer	6.61e-05	0.000396	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HES1—hematologic cancer	6.55e-05	0.000393	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—NCOR1—hematologic cancer	6.52e-05	0.000391	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CSF2—hematologic cancer	6.44e-05	0.000386	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FGF1—hematologic cancer	6.44e-05	0.000386	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MAP2K1—hematologic cancer	6.4e-05	0.000384	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CD—hematologic cancer	6.35e-05	0.000381	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FOXO1—hematologic cancer	6.35e-05	0.000381	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—IL2—hematologic cancer	6.35e-05	0.000381	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PDGFRB—hematologic cancer	6.34e-05	0.00038	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CA—hematologic cancer	6.29e-05	0.000377	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CB—hematologic cancer	6.28e-05	0.000376	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PDGFRA—hematologic cancer	6.24e-05	0.000374	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—KRAS—hematologic cancer	6.22e-05	0.000373	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—JAK1—hematologic cancer	6.22e-05	0.000373	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PRKCG—hematologic cancer	6.22e-05	0.000373	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FGF2—hematologic cancer	6.08e-05	0.000365	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3R1—hematologic cancer	6e-05	0.00036	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—JAK2—hematologic cancer	5.83e-05	0.00035	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IL2RA—hematologic cancer	5.81e-05	0.000348	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—IL2—hematologic cancer	5.76e-05	0.000346	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TERT—hematologic cancer	5.74e-05	0.000344	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CA—hematologic cancer	5.72e-05	0.000343	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MDM2—hematologic cancer	5.69e-05	0.000341	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PDGFB—hematologic cancer	5.61e-05	0.000336	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CB—hematologic cancer	5.54e-05	0.000332	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MTOR—hematologic cancer	5.54e-05	0.000332	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TSC2—hematologic cancer	5.48e-05	0.000329	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—HRAS—hematologic cancer	5.29e-05	0.000317	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FGFR3—hematologic cancer	5.27e-05	0.000316	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MAPK14—hematologic cancer	5.22e-05	0.000313	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CDKN1B—hematologic cancer	5.2e-05	0.000312	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—AKT1—hematologic cancer	5.14e-05	0.000308	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ESR1—hematologic cancer	5.12e-05	0.000307	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CASP3—hematologic cancer	5.09e-05	0.000306	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—IL2—hematologic cancer	5.09e-05	0.000305	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—IL6—hematologic cancer	5.06e-05	0.000304	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FN1—hematologic cancer	5.06e-05	0.000303	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—BAD—hematologic cancer	5e-05	0.0003	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—NFKBIA—hematologic cancer	5e-05	0.0003	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CCND1—hematologic cancer	4.96e-05	0.000297	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—JUN—hematologic cancer	4.95e-05	0.000297	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—NOTCH1—hematologic cancer	4.95e-05	0.000297	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CD80—hematologic cancer	4.85e-05	0.000291	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CG—hematologic cancer	4.84e-05	0.00029	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—KIT—hematologic cancer	4.84e-05	0.00029	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—NRAS—hematologic cancer	4.84e-05	0.00029	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CDKN1A—hematologic cancer	4.8e-05	0.000288	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PTEN—hematologic cancer	4.79e-05	0.000287	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PTPN11—hematologic cancer	4.75e-05	0.000285	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MAPK8—hematologic cancer	4.68e-05	0.000281	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—AKT1—hematologic cancer	4.67e-05	0.00028	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—MAPK3—hematologic cancer	4.63e-05	0.000278	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CREB1—hematologic cancer	4.61e-05	0.000276	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—EP300—hematologic cancer	4.56e-05	0.000274	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—BRAF—hematologic cancer	4.55e-05	0.000273	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CCL2—hematologic cancer	4.51e-05	0.00027	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IL6R—hematologic cancer	4.49e-05	0.000269	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CREBBP—hematologic cancer	4.49e-05	0.000269	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—SRC—hematologic cancer	4.44e-05	0.000266	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—VEGFA—hematologic cancer	4.32e-05	0.000259	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MAP2K1—hematologic cancer	4.28e-05	0.000257	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—STAT3—hematologic cancer	4.28e-05	0.000257	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—NRAS—hematologic cancer	4.27e-05	0.000256	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CD—hematologic cancer	4.25e-05	0.000255	CbGpPWpGaD
Goserelin—Hyperhidrosis—Prednisone—hematologic cancer	4.22e-05	6.89e-05	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CA—hematologic cancer	4.21e-05	0.000253	CbGpPWpGaD
Goserelin—Vision blurred—Methotrexate—hematologic cancer	4.21e-05	6.87e-05	CcSEcCtD
Goserelin—Mental disorder—Epirubicin—hematologic cancer	4.21e-05	6.87e-05	CcSEcCtD
Goserelin—Rash—Cisplatin—hematologic cancer	4.19e-05	6.84e-05	CcSEcCtD
Goserelin—Dermatitis—Cisplatin—hematologic cancer	4.19e-05	6.83e-05	CcSEcCtD
Goserelin—Malnutrition—Epirubicin—hematologic cancer	4.18e-05	6.83e-05	CcSEcCtD
Goserelin—Erythema—Epirubicin—hematologic cancer	4.18e-05	6.83e-05	CcSEcCtD
Goserelin—Diarrhoea—Etoposide—hematologic cancer	4.17e-05	6.8e-05	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—KRAS—hematologic cancer	4.16e-05	0.00025	CbGpPWpGaD
Goserelin—Anorexia—Prednisone—hematologic cancer	4.16e-05	6.79e-05	CcSEcCtD
Goserelin—Eye disorder—Doxorubicin—hematologic cancer	4.16e-05	6.78e-05	CcSEcCtD
Goserelin—Ill-defined disorder—Methotrexate—hematologic cancer	4.15e-05	6.77e-05	CcSEcCtD
Goserelin—Anaemia—Methotrexate—hematologic cancer	4.13e-05	6.74e-05	CcSEcCtD
Goserelin—Feeling abnormal—Dexamethasone—hematologic cancer	4.13e-05	6.74e-05	CcSEcCtD
Goserelin—Feeling abnormal—Betamethasone—hematologic cancer	4.13e-05	6.74e-05	CcSEcCtD
Goserelin—Cardiac disorder—Doxorubicin—hematologic cancer	4.13e-05	6.73e-05	CcSEcCtD
Goserelin—Flatulence—Epirubicin—hematologic cancer	4.12e-05	6.73e-05	CcSEcCtD
Goserelin—Tension—Epirubicin—hematologic cancer	4.11e-05	6.7e-05	CcSEcCtD
Goserelin—Gastrointestinal pain—Betamethasone—hematologic cancer	4.1e-05	6.69e-05	CcSEcCtD
Goserelin—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.1e-05	6.69e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—MAPK3—hematologic cancer	4.09e-05	0.000245	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FGF2—hematologic cancer	4.07e-05	0.000244	CbGpPWpGaD
Goserelin—Hypersensitivity—Triamcinolone—hematologic cancer	4.07e-05	6.64e-05	CcSEcCtD
Goserelin—Nervousness—Epirubicin—hematologic cancer	4.06e-05	6.63e-05	CcSEcCtD
Goserelin—Back pain—Epirubicin—hematologic cancer	4.05e-05	6.6e-05	CcSEcCtD
Goserelin—Angiopathy—Doxorubicin—hematologic cancer	4.03e-05	6.58e-05	CcSEcCtD
Goserelin—Malaise—Methotrexate—hematologic cancer	4.03e-05	6.58e-05	CcSEcCtD
Goserelin—Dizziness—Etoposide—hematologic cancer	4.03e-05	6.57e-05	CcSEcCtD
Goserelin—Muscle spasms—Epirubicin—hematologic cancer	4.02e-05	6.56e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—PIK3R1—hematologic cancer	4.02e-05	0.000241	CbGpPWpGaD
Goserelin—Immune system disorder—Doxorubicin—hematologic cancer	4.02e-05	6.55e-05	CcSEcCtD
Goserelin—Leukopenia—Methotrexate—hematologic cancer	4e-05	6.53e-05	CcSEcCtD
Goserelin—Chills—Doxorubicin—hematologic cancer	3.99e-05	6.51e-05	CcSEcCtD
Goserelin—Urticaria—Betamethasone—hematologic cancer	3.98e-05	6.5e-05	CcSEcCtD
Goserelin—Urticaria—Dexamethasone—hematologic cancer	3.98e-05	6.5e-05	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.98e-05	6.49e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—MYC—hematologic cancer	3.98e-05	0.000239	CbGpPWpGaD
Goserelin—Dizziness—Prednisolone—hematologic cancer	3.97e-05	6.48e-05	CcSEcCtD
Goserelin—Arrhythmia—Doxorubicin—hematologic cancer	3.97e-05	6.48e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—TGFB1—hematologic cancer	3.97e-05	0.000238	CbGpPWpGaD
Goserelin—Asthenia—Triamcinolone—hematologic cancer	3.96e-05	6.47e-05	CcSEcCtD
Goserelin—Body temperature increased—Betamethasone—hematologic cancer	3.96e-05	6.47e-05	CcSEcCtD
Goserelin—Abdominal pain—Dexamethasone—hematologic cancer	3.96e-05	6.47e-05	CcSEcCtD
Goserelin—Abdominal pain—Betamethasone—hematologic cancer	3.96e-05	6.47e-05	CcSEcCtD
Goserelin—Body temperature increased—Dexamethasone—hematologic cancer	3.96e-05	6.47e-05	CcSEcCtD
Goserelin—Nausea—Cisplatin—hematologic cancer	3.95e-05	6.44e-05	CcSEcCtD
Goserelin—Insomnia—Prednisone—hematologic cancer	3.95e-05	6.44e-05	CcSEcCtD
Goserelin—Vision blurred—Epirubicin—hematologic cancer	3.94e-05	6.43e-05	CcSEcCtD
Goserelin—Alopecia—Doxorubicin—hematologic cancer	3.93e-05	6.41e-05	CcSEcCtD
Goserelin—Paraesthesia—Prednisone—hematologic cancer	3.92e-05	6.4e-05	CcSEcCtD
Goserelin—Pruritus—Triamcinolone—hematologic cancer	3.91e-05	6.38e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—JAK2—hematologic cancer	3.9e-05	0.000234	CbGpPWpGaD
Goserelin—Cough—Methotrexate—hematologic cancer	3.9e-05	6.36e-05	CcSEcCtD
Goserelin—Mental disorder—Doxorubicin—hematologic cancer	3.9e-05	6.36e-05	CcSEcCtD
Goserelin—Ill-defined disorder—Epirubicin—hematologic cancer	3.88e-05	6.33e-05	CcSEcCtD
Goserelin—Convulsion—Methotrexate—hematologic cancer	3.87e-05	6.32e-05	CcSEcCtD
Goserelin—Vomiting—Etoposide—hematologic cancer	3.87e-05	6.32e-05	CcSEcCtD
Goserelin—Malnutrition—Doxorubicin—hematologic cancer	3.87e-05	6.32e-05	CcSEcCtD
Goserelin—Erythema—Doxorubicin—hematologic cancer	3.87e-05	6.32e-05	CcSEcCtD
Goserelin—Anaemia—Epirubicin—hematologic cancer	3.87e-05	6.31e-05	CcSEcCtD
Goserelin—Dyspepsia—Prednisone—hematologic cancer	3.84e-05	6.27e-05	CcSEcCtD
Goserelin—Rash—Etoposide—hematologic cancer	3.84e-05	6.27e-05	CcSEcCtD
Goserelin—Dermatitis—Etoposide—hematologic cancer	3.84e-05	6.26e-05	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—PIK3CA—hematologic cancer	3.83e-05	0.000229	CbGpPWpGaD
Goserelin—Headache—Etoposide—hematologic cancer	3.82e-05	6.23e-05	CcSEcCtD
Goserelin—Flatulence—Doxorubicin—hematologic cancer	3.81e-05	6.22e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—MDM2—hematologic cancer	3.81e-05	0.000229	CbGpPWpGaD
Goserelin—Arthralgia—Methotrexate—hematologic cancer	3.81e-05	6.21e-05	CcSEcCtD
Goserelin—Chest pain—Methotrexate—hematologic cancer	3.81e-05	6.21e-05	CcSEcCtD
Goserelin—Myalgia—Methotrexate—hematologic cancer	3.81e-05	6.21e-05	CcSEcCtD
Goserelin—Tension—Doxorubicin—hematologic cancer	3.8e-05	6.2e-05	CcSEcCtD
Goserelin—Decreased appetite—Prednisone—hematologic cancer	3.79e-05	6.19e-05	CcSEcCtD
Goserelin—Rash—Prednisolone—hematologic cancer	3.79e-05	6.18e-05	CcSEcCtD
Goserelin—Dermatitis—Prednisolone—hematologic cancer	3.78e-05	6.17e-05	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.78e-05	6.17e-05	CcSEcCtD
Goserelin—Malaise—Epirubicin—hematologic cancer	3.77e-05	6.16e-05	CcSEcCtD
Goserelin—Fatigue—Prednisone—hematologic cancer	3.76e-05	6.14e-05	CcSEcCtD
Goserelin—Headache—Prednisolone—hematologic cancer	3.76e-05	6.14e-05	CcSEcCtD
Goserelin—Discomfort—Methotrexate—hematologic cancer	3.76e-05	6.13e-05	CcSEcCtD
Goserelin—Nervousness—Doxorubicin—hematologic cancer	3.76e-05	6.13e-05	CcSEcCtD
Goserelin—Leukopenia—Epirubicin—hematologic cancer	3.74e-05	6.11e-05	CcSEcCtD
Goserelin—Back pain—Doxorubicin—hematologic cancer	3.74e-05	6.11e-05	CcSEcCtD
Goserelin—Constipation—Prednisone—hematologic cancer	3.73e-05	6.09e-05	CcSEcCtD
Goserelin—Muscle spasms—Doxorubicin—hematologic cancer	3.72e-05	6.07e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—MTOR—hematologic cancer	3.71e-05	0.000222	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CB—hematologic cancer	3.71e-05	0.000222	CbGpPWpGaD
Goserelin—Palpitations—Epirubicin—hematologic cancer	3.7e-05	6.03e-05	CcSEcCtD
Goserelin—Confusional state—Methotrexate—hematologic cancer	3.68e-05	6e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—KRAS—hematologic cancer	3.67e-05	0.00022	CbGpPWpGaD
Goserelin—Dizziness—Triamcinolone—hematologic cancer	3.65e-05	5.96e-05	CcSEcCtD
Goserelin—Cough—Epirubicin—hematologic cancer	3.65e-05	5.96e-05	CcSEcCtD
Goserelin—Anaphylactic shock—Methotrexate—hematologic cancer	3.65e-05	5.95e-05	CcSEcCtD
Goserelin—Vision blurred—Doxorubicin—hematologic cancer	3.65e-05	5.95e-05	CcSEcCtD
Goserelin—Convulsion—Epirubicin—hematologic cancer	3.62e-05	5.91e-05	CcSEcCtD
Goserelin—Infection—Methotrexate—hematologic cancer	3.62e-05	5.91e-05	CcSEcCtD
Goserelin—Nausea—Etoposide—hematologic cancer	3.62e-05	5.9e-05	CcSEcCtD
Goserelin—Hypertension—Epirubicin—hematologic cancer	3.61e-05	5.89e-05	CcSEcCtD
Goserelin—Feeling abnormal—Prednisone—hematologic cancer	3.6e-05	5.87e-05	CcSEcCtD
Goserelin—Asthenia—Dexamethasone—hematologic cancer	3.6e-05	5.87e-05	CcSEcCtD
Goserelin—Asthenia—Betamethasone—hematologic cancer	3.6e-05	5.87e-05	CcSEcCtD
Goserelin—Ill-defined disorder—Doxorubicin—hematologic cancer	3.59e-05	5.86e-05	CcSEcCtD
Goserelin—Nervous system disorder—Methotrexate—hematologic cancer	3.58e-05	5.84e-05	CcSEcCtD
Goserelin—Anaemia—Doxorubicin—hematologic cancer	3.58e-05	5.84e-05	CcSEcCtD
Goserelin—Thrombocytopenia—Methotrexate—hematologic cancer	3.57e-05	5.83e-05	CcSEcCtD
Goserelin—Gastrointestinal pain—Prednisone—hematologic cancer	3.57e-05	5.82e-05	CcSEcCtD
Goserelin—Nausea—Prednisolone—hematologic cancer	3.57e-05	5.82e-05	CcSEcCtD
Goserelin—Arthralgia—Epirubicin—hematologic cancer	3.56e-05	5.81e-05	CcSEcCtD
Goserelin—Chest pain—Epirubicin—hematologic cancer	3.56e-05	5.81e-05	CcSEcCtD
Goserelin—Myalgia—Epirubicin—hematologic cancer	3.56e-05	5.81e-05	CcSEcCtD
Goserelin—Anxiety—Epirubicin—hematologic cancer	3.55e-05	5.79e-05	CcSEcCtD
Goserelin—Pruritus—Betamethasone—hematologic cancer	3.55e-05	5.79e-05	CcSEcCtD
Goserelin—Pruritus—Dexamethasone—hematologic cancer	3.55e-05	5.79e-05	CcSEcCtD
Goserelin—Skin disorder—Methotrexate—hematologic cancer	3.54e-05	5.78e-05	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—HRAS—hematologic cancer	3.54e-05	0.000212	CbGpPWpGaD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.54e-05	5.77e-05	CcSEcCtD
Goserelin—Hyperhidrosis—Methotrexate—hematologic cancer	3.53e-05	5.75e-05	CcSEcCtD
Goserelin—Discomfort—Epirubicin—hematologic cancer	3.52e-05	5.74e-05	CcSEcCtD
Goserelin—Vomiting—Triamcinolone—hematologic cancer	3.51e-05	5.73e-05	CcSEcCtD
Goserelin—Malaise—Doxorubicin—hematologic cancer	3.49e-05	5.7e-05	CcSEcCtD
Goserelin—Rash—Triamcinolone—hematologic cancer	3.48e-05	5.68e-05	CcSEcCtD
Goserelin—Dry mouth—Epirubicin—hematologic cancer	3.48e-05	5.68e-05	CcSEcCtD
Goserelin—Dermatitis—Triamcinolone—hematologic cancer	3.48e-05	5.68e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CDKN1B—hematologic cancer	3.48e-05	0.000209	CbGpPWpGaD
Goserelin—Anorexia—Methotrexate—hematologic cancer	3.48e-05	5.67e-05	CcSEcCtD
Goserelin—Urticaria—Prednisone—hematologic cancer	3.47e-05	5.66e-05	CcSEcCtD
Goserelin—Leukopenia—Doxorubicin—hematologic cancer	3.46e-05	5.65e-05	CcSEcCtD
Goserelin—Headache—Triamcinolone—hematologic cancer	3.46e-05	5.65e-05	CcSEcCtD
Goserelin—Body temperature increased—Prednisone—hematologic cancer	3.45e-05	5.63e-05	CcSEcCtD
Goserelin—Abdominal pain—Prednisone—hematologic cancer	3.45e-05	5.63e-05	CcSEcCtD
Goserelin—Confusional state—Epirubicin—hematologic cancer	3.44e-05	5.62e-05	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—AKT1—hematologic cancer	3.44e-05	0.000206	CbGpPWpGaD
Goserelin—Diarrhoea—Dexamethasone—hematologic cancer	3.43e-05	5.6e-05	CcSEcCtD
Goserelin—Diarrhoea—Betamethasone—hematologic cancer	3.43e-05	5.6e-05	CcSEcCtD
Goserelin—Palpitations—Doxorubicin—hematologic cancer	3.42e-05	5.58e-05	CcSEcCtD
Goserelin—Oedema—Epirubicin—hematologic cancer	3.41e-05	5.57e-05	CcSEcCtD
Goserelin—Anaphylactic shock—Epirubicin—hematologic cancer	3.41e-05	5.57e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CASP3—hematologic cancer	3.41e-05	0.000205	CbGpPWpGaD
Goserelin—Hypotension—Methotrexate—hematologic cancer	3.41e-05	5.56e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—IL2—hematologic cancer	3.41e-05	0.000204	CbGpPWpGaD
Goserelin—Infection—Epirubicin—hematologic cancer	3.39e-05	5.53e-05	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—IL6—hematologic cancer	3.39e-05	0.000203	CbGpPWpGaD
Goserelin—Cough—Doxorubicin—hematologic cancer	3.38e-05	5.51e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—PIK3CA—hematologic cancer	3.38e-05	0.000203	CbGpPWpGaD
Goserelin—Shock—Epirubicin—hematologic cancer	3.36e-05	5.48e-05	CcSEcCtD
Goserelin—Convulsion—Doxorubicin—hematologic cancer	3.35e-05	5.47e-05	CcSEcCtD
Goserelin—Nervous system disorder—Epirubicin—hematologic cancer	3.35e-05	5.46e-05	CcSEcCtD
Goserelin—Thrombocytopenia—Epirubicin—hematologic cancer	3.34e-05	5.45e-05	CcSEcCtD
Goserelin—Hypertension—Doxorubicin—hematologic cancer	3.34e-05	5.45e-05	CcSEcCtD
Goserelin—Tachycardia—Epirubicin—hematologic cancer	3.33e-05	5.44e-05	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.32e-05	5.42e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CCND1—hematologic cancer	3.32e-05	0.000199	CbGpPWpGaD
Goserelin—Skin disorder—Epirubicin—hematologic cancer	3.32e-05	5.41e-05	CcSEcCtD
Goserelin—Dizziness—Betamethasone—hematologic cancer	3.31e-05	5.41e-05	CcSEcCtD
Goserelin—Dizziness—Dexamethasone—hematologic cancer	3.31e-05	5.41e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—JUN—hematologic cancer	3.31e-05	0.000199	CbGpPWpGaD
Goserelin—Hyperhidrosis—Epirubicin—hematologic cancer	3.3e-05	5.39e-05	CcSEcCtD
Goserelin—Insomnia—Methotrexate—hematologic cancer	3.3e-05	5.38e-05	CcSEcCtD
Goserelin—Arthralgia—Doxorubicin—hematologic cancer	3.3e-05	5.38e-05	CcSEcCtD
Goserelin—Chest pain—Doxorubicin—hematologic cancer	3.3e-05	5.38e-05	CcSEcCtD
Goserelin—Myalgia—Doxorubicin—hematologic cancer	3.3e-05	5.38e-05	CcSEcCtD
Goserelin—Anxiety—Doxorubicin—hematologic cancer	3.28e-05	5.36e-05	CcSEcCtD
Goserelin—Nausea—Triamcinolone—hematologic cancer	3.28e-05	5.35e-05	CcSEcCtD
Goserelin—Paraesthesia—Methotrexate—hematologic cancer	3.28e-05	5.34e-05	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.27e-05	5.34e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—TP53—hematologic cancer	3.27e-05	0.000196	CbGpPWpGaD
Goserelin—Discomfort—Doxorubicin—hematologic cancer	3.26e-05	5.31e-05	CcSEcCtD
Goserelin—Anorexia—Epirubicin—hematologic cancer	3.25e-05	5.31e-05	CcSEcCtD
Goserelin—Dyspnoea—Methotrexate—hematologic cancer	3.25e-05	5.31e-05	CcSEcCtD
Goserelin—Somnolence—Methotrexate—hematologic cancer	3.24e-05	5.29e-05	CcSEcCtD
Goserelin—Dry mouth—Doxorubicin—hematologic cancer	3.22e-05	5.26e-05	CcSEcCtD
Goserelin—Hypersensitivity—Prednisone—hematologic cancer	3.22e-05	5.25e-05	CcSEcCtD
Goserelin—Dyspepsia—Methotrexate—hematologic cancer	3.21e-05	5.24e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CDKN1A—hematologic cancer	3.21e-05	0.000193	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PTEN—hematologic cancer	3.2e-05	0.000192	CbGpPWpGaD
Goserelin—Hypotension—Epirubicin—hematologic cancer	3.19e-05	5.21e-05	CcSEcCtD
Goserelin—Vomiting—Betamethasone—hematologic cancer	3.19e-05	5.2e-05	CcSEcCtD
Goserelin—Vomiting—Dexamethasone—hematologic cancer	3.19e-05	5.2e-05	CcSEcCtD
Goserelin—Confusional state—Doxorubicin—hematologic cancer	3.19e-05	5.2e-05	CcSEcCtD
Goserelin—Decreased appetite—Methotrexate—hematologic cancer	3.17e-05	5.17e-05	CcSEcCtD
Goserelin—Rash—Dexamethasone—hematologic cancer	3.16e-05	5.16e-05	CcSEcCtD
Goserelin—Rash—Betamethasone—hematologic cancer	3.16e-05	5.16e-05	CcSEcCtD
Goserelin—Anaphylactic shock—Doxorubicin—hematologic cancer	3.16e-05	5.15e-05	CcSEcCtD
Goserelin—Oedema—Doxorubicin—hematologic cancer	3.16e-05	5.15e-05	CcSEcCtD
Goserelin—Dermatitis—Dexamethasone—hematologic cancer	3.16e-05	5.15e-05	CcSEcCtD
Goserelin—Dermatitis—Betamethasone—hematologic cancer	3.16e-05	5.15e-05	CcSEcCtD
Goserelin—Fatigue—Methotrexate—hematologic cancer	3.15e-05	5.13e-05	CcSEcCtD
Goserelin—Headache—Dexamethasone—hematologic cancer	3.14e-05	5.12e-05	CcSEcCtD
Goserelin—Headache—Betamethasone—hematologic cancer	3.14e-05	5.12e-05	CcSEcCtD
Goserelin—Infection—Doxorubicin—hematologic cancer	3.14e-05	5.12e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—MAPK8—hematologic cancer	3.13e-05	0.000188	CbGpPWpGaD
Goserelin—Asthenia—Prednisone—hematologic cancer	3.13e-05	5.11e-05	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—AKT1—hematologic cancer	3.13e-05	0.000187	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HRAS—hematologic cancer	3.12e-05	0.000187	CbGpPWpGaD
Goserelin—Pain—Methotrexate—hematologic cancer	3.12e-05	5.09e-05	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.11e-05	5.08e-05	CcSEcCtD
Goserelin—Shock—Doxorubicin—hematologic cancer	3.11e-05	5.07e-05	CcSEcCtD
Goserelin—Nervous system disorder—Doxorubicin—hematologic cancer	3.1e-05	5.05e-05	CcSEcCtD
Goserelin—Thrombocytopenia—Doxorubicin—hematologic cancer	3.09e-05	5.05e-05	CcSEcCtD
Goserelin—Pruritus—Prednisone—hematologic cancer	3.09e-05	5.04e-05	CcSEcCtD
Goserelin—Insomnia—Epirubicin—hematologic cancer	3.09e-05	5.04e-05	CcSEcCtD
Goserelin—Tachycardia—Doxorubicin—hematologic cancer	3.08e-05	5.03e-05	CcSEcCtD
Goserelin—Skin disorder—Doxorubicin—hematologic cancer	3.07e-05	5.01e-05	CcSEcCtD
Goserelin—Paraesthesia—Epirubicin—hematologic cancer	3.07e-05	5e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—EP300—hematologic cancer	3.06e-05	0.000183	CbGpPWpGaD
Goserelin—Hyperhidrosis—Doxorubicin—hematologic cancer	3.05e-05	4.98e-05	CcSEcCtD
Goserelin—Dyspnoea—Epirubicin—hematologic cancer	3.04e-05	4.97e-05	CcSEcCtD
Goserelin—Somnolence—Epirubicin—hematologic cancer	3.04e-05	4.95e-05	CcSEcCtD
Goserelin—Anorexia—Doxorubicin—hematologic cancer	3.01e-05	4.91e-05	CcSEcCtD
Goserelin—Feeling abnormal—Methotrexate—hematologic cancer	3.01e-05	4.91e-05	CcSEcCtD
Goserelin—Dyspepsia—Epirubicin—hematologic cancer	3.01e-05	4.9e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—IL6—hematologic cancer	2.99e-05	0.000179	CbGpPWpGaD
Goserelin—Diarrhoea—Prednisone—hematologic cancer	2.99e-05	4.87e-05	CcSEcCtD
Goserelin—Gastrointestinal pain—Methotrexate—hematologic cancer	2.98e-05	4.87e-05	CcSEcCtD
Goserelin—Nausea—Betamethasone—hematologic cancer	2.98e-05	4.86e-05	CcSEcCtD
Goserelin—Nausea—Dexamethasone—hematologic cancer	2.98e-05	4.86e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—SRC—hematologic cancer	2.97e-05	0.000178	CbGpPWpGaD
Goserelin—Decreased appetite—Epirubicin—hematologic cancer	2.97e-05	4.84e-05	CcSEcCtD
Goserelin—Hypotension—Doxorubicin—hematologic cancer	2.95e-05	4.82e-05	CcSEcCtD
Goserelin—Fatigue—Epirubicin—hematologic cancer	2.94e-05	4.8e-05	CcSEcCtD
Goserelin—Constipation—Epirubicin—hematologic cancer	2.92e-05	4.76e-05	CcSEcCtD
Goserelin—Pain—Epirubicin—hematologic cancer	2.92e-05	4.76e-05	CcSEcCtD
Goserelin—Urticaria—Methotrexate—hematologic cancer	2.9e-05	4.73e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—VEGFA—hematologic cancer	2.89e-05	0.000174	CbGpPWpGaD
Goserelin—Dizziness—Prednisone—hematologic cancer	2.89e-05	4.71e-05	CcSEcCtD
Goserelin—Abdominal pain—Methotrexate—hematologic cancer	2.88e-05	4.71e-05	CcSEcCtD
Goserelin—Body temperature increased—Methotrexate—hematologic cancer	2.88e-05	4.71e-05	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.88e-05	4.7e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—STAT3—hematologic cancer	2.87e-05	0.000172	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—NRAS—hematologic cancer	2.86e-05	0.000171	CbGpPWpGaD
Goserelin—Insomnia—Doxorubicin—hematologic cancer	2.86e-05	4.66e-05	CcSEcCtD
Goserelin—Paraesthesia—Doxorubicin—hematologic cancer	2.84e-05	4.63e-05	CcSEcCtD
Goserelin—Dyspnoea—Doxorubicin—hematologic cancer	2.82e-05	4.6e-05	CcSEcCtD
Goserelin—Feeling abnormal—Epirubicin—hematologic cancer	2.81e-05	4.59e-05	CcSEcCtD
Goserelin—Somnolence—Doxorubicin—hematologic cancer	2.81e-05	4.58e-05	CcSEcCtD
Goserelin—Gastrointestinal pain—Epirubicin—hematologic cancer	2.79e-05	4.56e-05	CcSEcCtD
Goserelin—Dyspepsia—Doxorubicin—hematologic cancer	2.78e-05	4.54e-05	CcSEcCtD
Goserelin—Vomiting—Prednisone—hematologic cancer	2.78e-05	4.53e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—AKT1—hematologic cancer	2.76e-05	0.000165	CbGpPWpGaD
Goserelin—Rash—Prednisone—hematologic cancer	2.75e-05	4.49e-05	CcSEcCtD
Goserelin—Dermatitis—Prednisone—hematologic cancer	2.75e-05	4.49e-05	CcSEcCtD
Goserelin—Decreased appetite—Doxorubicin—hematologic cancer	2.75e-05	4.48e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—MAPK3—hematologic cancer	2.74e-05	0.000164	CbGpPWpGaD
Goserelin—Headache—Prednisone—hematologic cancer	2.73e-05	4.46e-05	CcSEcCtD
Goserelin—Fatigue—Doxorubicin—hematologic cancer	2.72e-05	4.44e-05	CcSEcCtD
Goserelin—Urticaria—Epirubicin—hematologic cancer	2.71e-05	4.43e-05	CcSEcCtD
Goserelin—Pain—Doxorubicin—hematologic cancer	2.7e-05	4.41e-05	CcSEcCtD
Goserelin—Constipation—Doxorubicin—hematologic cancer	2.7e-05	4.41e-05	CcSEcCtD
Goserelin—Abdominal pain—Epirubicin—hematologic cancer	2.7e-05	4.4e-05	CcSEcCtD
Goserelin—Body temperature increased—Epirubicin—hematologic cancer	2.7e-05	4.4e-05	CcSEcCtD
Goserelin—Hypersensitivity—Methotrexate—hematologic cancer	2.69e-05	4.39e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—MYC—hematologic cancer	2.66e-05	0.00016	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TGFB1—hematologic cancer	2.66e-05	0.000159	CbGpPWpGaD
Goserelin—Asthenia—Methotrexate—hematologic cancer	2.62e-05	4.27e-05	CcSEcCtD
Goserelin—Feeling abnormal—Doxorubicin—hematologic cancer	2.6e-05	4.25e-05	CcSEcCtD
Goserelin—Nausea—Prednisone—hematologic cancer	2.59e-05	4.23e-05	CcSEcCtD
Goserelin—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.58e-05	4.21e-05	CcSEcCtD
Goserelin—Pruritus—Methotrexate—hematologic cancer	2.58e-05	4.21e-05	CcSEcCtD
Goserelin—Hypersensitivity—Epirubicin—hematologic cancer	2.52e-05	4.1e-05	CcSEcCtD
Goserelin—Urticaria—Doxorubicin—hematologic cancer	2.51e-05	4.09e-05	CcSEcCtD
Goserelin—Abdominal pain—Doxorubicin—hematologic cancer	2.5e-05	4.07e-05	CcSEcCtD
Goserelin—Body temperature increased—Doxorubicin—hematologic cancer	2.5e-05	4.07e-05	CcSEcCtD
Goserelin—Diarrhoea—Methotrexate—hematologic cancer	2.5e-05	4.07e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—KRAS—hematologic cancer	2.46e-05	0.000148	CbGpPWpGaD
Goserelin—Asthenia—Epirubicin—hematologic cancer	2.45e-05	4e-05	CcSEcCtD
Goserelin—Pruritus—Epirubicin—hematologic cancer	2.42e-05	3.94e-05	CcSEcCtD
Goserelin—Dizziness—Methotrexate—hematologic cancer	2.41e-05	3.94e-05	CcSEcCtD
Goserelin—Diarrhoea—Epirubicin—hematologic cancer	2.34e-05	3.81e-05	CcSEcCtD
Goserelin—Hypersensitivity—Doxorubicin—hematologic cancer	2.33e-05	3.8e-05	CcSEcCtD
Goserelin—Vomiting—Methotrexate—hematologic cancer	2.32e-05	3.78e-05	CcSEcCtD
Goserelin—Rash—Methotrexate—hematologic cancer	2.3e-05	3.75e-05	CcSEcCtD
Goserelin—Dermatitis—Methotrexate—hematologic cancer	2.3e-05	3.75e-05	CcSEcCtD
Goserelin—Headache—Methotrexate—hematologic cancer	2.29e-05	3.73e-05	CcSEcCtD
Goserelin—Asthenia—Doxorubicin—hematologic cancer	2.27e-05	3.7e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—PIK3CA—hematologic cancer	2.26e-05	0.000136	CbGpPWpGaD
Goserelin—Dizziness—Epirubicin—hematologic cancer	2.26e-05	3.68e-05	CcSEcCtD
Goserelin—Pruritus—Doxorubicin—hematologic cancer	2.24e-05	3.65e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—TP53—hematologic cancer	2.19e-05	0.000131	CbGpPWpGaD
Goserelin—Vomiting—Epirubicin—hematologic cancer	2.17e-05	3.54e-05	CcSEcCtD
Goserelin—Nausea—Methotrexate—hematologic cancer	2.17e-05	3.54e-05	CcSEcCtD
Goserelin—Diarrhoea—Doxorubicin—hematologic cancer	2.16e-05	3.53e-05	CcSEcCtD
Goserelin—Rash—Epirubicin—hematologic cancer	2.15e-05	3.51e-05	CcSEcCtD
Goserelin—Dermatitis—Epirubicin—hematologic cancer	2.15e-05	3.51e-05	CcSEcCtD
Goserelin—Headache—Epirubicin—hematologic cancer	2.14e-05	3.49e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—HRAS—hematologic cancer	2.09e-05	0.000125	CbGpPWpGaD
Goserelin—Dizziness—Doxorubicin—hematologic cancer	2.09e-05	3.41e-05	CcSEcCtD
Goserelin—Nausea—Epirubicin—hematologic cancer	2.03e-05	3.31e-05	CcSEcCtD
Goserelin—Vomiting—Doxorubicin—hematologic cancer	2.01e-05	3.28e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—IL6—hematologic cancer	2e-05	0.00012	CbGpPWpGaD
Goserelin—Rash—Doxorubicin—hematologic cancer	1.99e-05	3.25e-05	CcSEcCtD
Goserelin—Dermatitis—Doxorubicin—hematologic cancer	1.99e-05	3.25e-05	CcSEcCtD
Goserelin—Headache—Doxorubicin—hematologic cancer	1.98e-05	3.23e-05	CcSEcCtD
Goserelin—Nausea—Doxorubicin—hematologic cancer	1.88e-05	3.06e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—AKT1—hematologic cancer	1.85e-05	0.000111	CbGpPWpGaD
